Key Points
- Vir Biotechnology CEO Backer Marianne De sold 72,559 shares on April 6 at an average price of $9.16 for a total of $664,640.44 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding, reducing her stake by 7.11% to 948,145 shares (valued ≈ $8.69M).
- In the latest quarter Vir reported revenue of $64.07M (up 417.8% y/y) and beat EPS estimates (reported -$0.31 vs. -$0.42 consensus), but remains unprofitable with a negative ROE and a net margin of -638.88%, and analysts expect fiscal‑year EPS around -3.92.
- Analysts have trended positive, with several firms raising price targets (e.g., Morgan Stanley to $24) and the consensus rating at Moderate Buy with an average price target of $20.44.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CEO Backer Marianne De sold 72,559 shares of Vir Biotechnology stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $9.16, for a total value of $664,640.44. Following the completion of the sale, the chief executive officer owned 948,145 shares of the company's stock, valued at $8,685,008.20. The trade was a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Backer Marianne De also recently made the following trade(s):
- On Tuesday, February 24th, Backer Marianne De sold 14,762 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.53, for a total value of $140,681.86.
- On Monday, February 23rd, Backer Marianne De sold 19,039 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total value of $141,840.55.
Vir Biotechnology Stock Performance
NASDAQ VIR opened at $9.17 on Wednesday. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $10.94. The stock has a 50-day moving average of $8.58 and a 200 day moving average of $6.92. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -2.90 and a beta of 1.66.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. During the same period last year, the company earned ($0.76) EPS. Vir Biotechnology's revenue for the quarter was up 417.8% on a year-over-year basis. On average, equities analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in VIR. Raymond James Financial Inc. bought a new position in shares of Vir Biotechnology during the 2nd quarter valued at approximately $35,000. FNY Investment Advisers LLC purchased a new position in Vir Biotechnology in the 3rd quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company's stock worth $41,000 after purchasing an additional 1,390 shares in the last quarter. UMB Bank n.a. lifted its holdings in Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company's stock worth $43,000 after purchasing an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company's stock worth $46,000 after purchasing an additional 4,899 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several research firms recently commented on VIR. Evercore reiterated an "outperform" rating and issued a $18.00 price objective on shares of Vir Biotechnology in a report on Tuesday, February 24th. Morgan Stanley lifted their price objective on Vir Biotechnology from $20.00 to $24.00 and gave the stock an "overweight" rating in a report on Tuesday, February 24th. Leerink Partners reissued an "outperform" rating and issued a $20.00 target price on shares of Vir Biotechnology in a research report on Thursday, February 26th. HC Wainwright boosted their price target on Vir Biotechnology from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen upgraded Vir Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $20.44.
Get Our Latest Stock Analysis on VIR
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
